SCHEMBL7849673

SCHEMBL7849673

CCOC(=O)c1cc(C)c(C)cc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.58
HSD17B10 Q99714 5/20 0.58
TSHR P16473 2/20 0.52
GAA P10253 4/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA7 P43166 3/20 0.47
CA9 Q16790 3/20 0.47
CA14 Q9ULX7 3/20 0.47
LMNA P02545 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
MAOA P21397 1/20 0.47
KDM4E B2RXH2 5/20 0.46
HPGD P15428 2/20 0.46
MAPT P10636 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8802379 0.98 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL7471868 0.90 ALDH1A1 (0.63) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL15358099 0.86 ALDH1A1 (0.51) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL15358179 0.86 ALDH1A1 (0.51) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL16529387 0.86 ALDH1A1 (0.51) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL4625850 0.86 TSHR (0.61) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL27248533 0.84 HSD17B10 (0.50) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL10629350 0.84 KDM4E (0.56) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL15358021 0.83 ALDH1A1 (0.49) ALDH1A1HSD17B10TSHRGAAMAPK1
SCHEMBL15713806 0.81 ALDH1A1 (0.54) ALDH1A1HSD17B10TSHRGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
EP-0805812-B1 BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS ABBOTT LAB (US) 2001-06-13 EP disclosed
US-5792767-A TREATMENT OF BENIGN PROSTATIC HYPERTROPY ABBOTT LABORATORIES (US) 1998-08-11 US disclosed
WO-1996022991-A1 BICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS ABBOTT LABORATORIES (US) 1996-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1422/4885HSD17B10 749/4885TSHR 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.